Präventive Monotherapie mit Montelukast versus DNCG bei Kindern mit leichtem Asthma bronchiale - Ergebnisse einer explorativen Pilotstudie -

Liebke, C.; Sommerfeld, C; Wahn, Ulrich; Niggemann, B.

doi:10.1055/s-2001-13950

Cited by 6 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several previous studies have reported that montelukast monotherapy has been utilized to treat children with asthma, [30–33] its efficacy is still limited and also has a variety of adverse events. Thus, in order to improve its efficacy, alternative add-on therapy should be added to manage such disorder.…”

Section: Discussionmentioning

confidence: 99%

Exercise training as an adjunctive therapy to montelukast in children with mild asthma

Zhang

Yang

2019

Medicine

View full text Add to dashboard Cite

Background: This study investigated the effectiveness and safety of exercise training (ET) as an adjunctive therapy to montelukast for children with mild asthma (MA). Methods: A total of 72 children, ages 4 to 12 years with MA were randomly assigned to a treatment group or a control group at a ratio of 1:1. The subjects in the treatment group received ET plus montelukast, while the participants in the control group received montelukast alone. The primary endpoint was lung function, as measured by forced expiratory volume in 1 second (FEV 1 ) and ratio between FEV 1 and forced vital capacity (FEV 1 /FVC). The secondary endpoints included the symptom improvements, as measured by clinical assessment score, and quality of life (QoL), as assessed with Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ) scores. In addition, adverse events were also assessed during the period of this study. All outcomes were measured at baseline, at the end of 6-week treatment and 2-week follow-up after the treatment. Results: After 6-week treatment and 2-week follow-up, although ET plus montelukast did not show better effectiveness in improving lung function, as evaluated by the FEV 1 ( P > .05) and FEV 1 /FVC ( P > .05) than montelukast alone, significant relief in clinical symptoms ( P < .01), and improvement in QoL ( P < .01) have achieved. Additionally, both groups had similar safety profile. Conclusion: The results of this study showed that ET as an adjunctive therapy to montelukast may benefit for children with MA. Further studies are still needed to warrant the results of this study.

show abstract

Section: Discussionmentioning

confidence: 99%